SCHEMBL4240629

SCHEMBL4240629

CCC(CC)NC(=O)Nc1ccc(Oc2ccc(NC(=O)c3ccc(OC4CCN(C)CC4)cc3)cc2C)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 2/20 0.44
LCK P06239 1/20 0.44
MAPK14 Q16539 1/20 0.44
PKM P14618 1/20 0.42
MCHR1 Q99705 1/20 0.42
NAMPT P43490 2/20 0.41
HSP90AA1 P07900 1/20 0.41
HSP90AB1 P08238 1/20 0.41
CSF1R P07333 2/20 0.41
PGR P06401 1/20 0.41
AR P10275 1/20 0.41
KDM1A O60341 1/20 0.41
RCOR1 Q9UKL0 1/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
GSK3B P49841 5/20 0.40
DYRK1A Q13627 5/20 0.40
ERBB2 P04626 1/20 0.40
CLK2 P49760 2/20 0.40
CLK3 P49761 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4238778 0.93 SMN1; SMN2 (0.43) KDRLCKMAPK14PKMMCHR1
SCHEMBL4238290 0.93 CSF1R (0.43) PKMMCHR1NAMPTCSF1RPGR
SCHEMBL4236315 0.92 FGFR1 (0.43) KDRLCKMAPK14PKMMCHR1
SCHEMBL4237153 0.92 HRH3 (0.48) PKMNAMPTCSF1R
SCHEMBL4237761 0.92 HRH3 (0.44) PKMCSF1R
SCHEMBL4238295 0.92 PKM (0.41) KDRLCKMAPK14PKMNAMPT
SCHEMBL4228695 0.91 MCHR1 (0.44) PKMMCHR1NAMPTPGRAR
SCHEMBL4236318 0.91 MCHR1 (0.39) KDRLCKMAPK14PKMMCHR1
SCHEMBL4233740 0.91 MCHR1 (0.39) KDRLCKMAPK14PKMMCHR1
SCHEMBL4242521 0.91 HRH3 (0.42) PKMNAMPTCSF1RPGRAR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US claimed
EP-1879887-A2 NPY ANTAGONISTS, PREPARATION AND USE Cerep (FR) 2008-01-23 EP claimed
WO-2006108965-A2 NPY ANTAGONISTS, PREPARATION AND USE CEREP (FR) 2006-10-19 WO claimed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
EP-1879887-A2 NPY ANTAGONISTS, PREPARATION AND USE Cerep (FR) 2008-01-23 EP disclosed
WO-2006108965-A2 NPY ANTAGONISTS, PREPARATION AND USE CEREP (FR) 2006-10-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233910-A1 Npy antagonists, preparation and uses NPY1R, NPY5R, NPY2R KDR 1664/4885LCK 232/4885MAPK14 2468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.